The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima…
Hepatocellular carcinoma is one of the most common liver cancers and has a five-year survival rate of only 18%. China represents more than half of all diagnosed cases of liver cancer worldwide. The…
Epi Data Slicer
Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…